We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Takeda Pharmaceutical has entered a research collaboration with Shattuck Labs to study and develop checkpoint fusion proteins that have the potential to be used as highly differentiated, advanced immunotherapies for cancer.
Takeda Pharmaceutical Company and Shattuck Labs announced they have entered into a research collaboration to explore and develop checkpoint fusion proteins,Takeda will hold options for exclusive global development and commercialization rights for up to fo